Parabilis Medicines, Inc.

Parabilis Medicines (PBLS) shows no cyber incidents or material red-flag 8-K filings in our 90-day detection window, suggesting operational stability in the recent period. However, low signal in a short window does not indicate comprehensive risk profile—the company's longer-term capital structure, equity dilution trajectory, and financing history require deeper analysis. The full $49 Report extends coverage to 12 months of filings, calculates dilution risk scores, contextualizes any 8-K events, and surfaces AI-detected risk signals across regulatory submissions. The full $49 Report adds quantified dilution metrics, 12-month filing context, and AI risk scoring across equity and operational dimensions.